# Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

> **NCT02020707** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 43 (actual)

## Conditions studied

- Cervical Adenocarcinoma
- Cervical Adenosarcoma
- Cervical Adenosquamous Carcinoma
- Cervical Carcinosarcoma
- Cervical Squamous Cell Carcinoma
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Mixed Cell Adenocarcinoma
- Endometrial Mucinous Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Undifferentiated Carcinoma
- Fallopian Tube Adenocarcinoma
- Fallopian Tube Carcinosarcoma
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Fallopian Tube Squamous Cell Carcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Fallopian Tube Undifferentiated Carcinoma
- Malignant Female Reproductive System Neoplasm
- Malignant Ovarian Clear Cell Tumor
- Malignant Ovarian Endometrioid Tumor
- Malignant Ovarian Epithelial Tumor
- Malignant Ovarian Mucinous Tumor
- Malignant Peritoneal Neoplasm
- Malignant Solid Neoplasm
- Ovarian Carcinosarcoma
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian High Grade Serous Adenocarcinoma
- Ovarian Mucinous Adenocarcinoma
- Ovarian Serous Adenocarcinoma
- Ovarian Transitional Cell Carcinoma
- Ovarian Undifferentiated Carcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Platinum-Sensitive Ovarian Carcinoma
- Primary Peritoneal Carcinosarcoma
- Primary Peritoneal Clear Cell Adenocarcinoma
- Primary Peritoneal Serous Adenocarcinoma
- Primary Peritoneal Transitional Cell Carcinoma
- Primary Peritoneal Undifferentiated Carcinoma
- Unresectable Melanoma
- Uterine Corpus Carcinosarcoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Nab-paclitaxel
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02020707
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-24
- **Primary completion:** 2024-07-18
- **Final completion:** 2024-07-18
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02020707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02020707, "Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02020707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*